Favorable cash repatriation rates and regulatory approvals for major healthcare deals have not brought an expected surge in mega-mergers among large US pharmaceutical companies, according to healthcare investment bankers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,